- Patent Title: Iminothiadiazinane dioxide derivatives as plasmepsin V inhibitors
-
Application No.: US16076387Application Date: 2017-02-22
-
Publication No.: US10464932B2Publication Date: 2019-11-05
- Inventor: Teresa De Haro Garcia , Martin Alexander Lowe , Malcolm Maccoss , Richard David Taylor , Zhaoning Zhu
- Applicant: UCB Biopharma SPRL
- Applicant Address: BE Brussels
- Assignee: UCB Biopharma SPRL
- Current Assignee: UCB Biopharma SPRL
- Current Assignee Address: BE Brussels
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: GB1603104.9 20160223
- International Application: PCT/EP2017/054023 WO 20170222
- International Announcement: WO2017/144517 WO 20170831
- Main IPC: C07D417/10
- IPC: C07D417/10 ; C07D417/14 ; A61P33/06

Abstract:
A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.
Public/Granted literature
- US20190040053A1 Iminothiadiazinane Dioxide Derivatives as Plasmepsin V Inhibitors Public/Granted day:2019-02-07
Information query